Skip to main content
Top
Published in: Endocrine Pathology 3/2007

01-09-2007

Follicular Variant Papillary Thyroid Carcinoma Arising in Struma Ovarii

Authors: Odette Boutross-Tadross, Remaa Saleh, Sylvia L. Asa

Published in: Endocrine Pathology | Issue 3/2007

Login to get access

Abstract

Struma ovarii is a rare monodermal ovarian teratoma in which thyroid tissue is the predominant or exclusive element. Malignant transformation is known to occur, usually as classical papillary thyroid carcinoma (PTC). However, the recognition of follicular variant PTC raises the possibility of similar malignancy arising in struma ovarii. We examined 13 cases of struma ovarii to determine if these lesions can exhibit histological, immunohistochemical, and/or molecular features of follicular variant PTC. Ten of these had atypical histology, cytologic features of PTC, and all ten showed diffuse positivity for CK19; eight of these were also positive for HMBE-1. Mutational analysis for BRAF identified no V600E mutations. However, seven of the ten cases with features of follicular variant PTC exhibited a rearranged in transformation (RET)/PTC rearrangement by reverse transcriptase polymerase chain reaction (RT-PCR). The three cases considered to be benign based on histologic and cytologic criteria were negative for CK19 and HBME-1 by immunohistochemistry, and had no evidence of BRAF mutation or ret/PTC-1 and ret/PTC-3 rearrangements. These results indicate that follicular variant PTC can occur in struma ovarii and that such lesions exhibit the same morphologic and immunohistochemical profile as follicular variant PTC in thyroid. The application of molecular testing to verify the diagnosis can be valuable, as these lesions may harbor ret/PTC gene rearrangements.
Literature
1.
go back to reference Scully R, Young R, Clement P. Tumors of the ovary, maldeveloped gonads and fallopian tubes. Atlas of tumor pathology, third series, fascicle. Washington, D.C.: Armed Forces Institute of Pathology, 1996. Scully R, Young R, Clement P. Tumors of the ovary, maldeveloped gonads and fallopian tubes. Atlas of tumor pathology, third series, fascicle. Washington, D.C.: Armed Forces Institute of Pathology, 1996.
3.
go back to reference Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol 12(4):333–43, 1993.PubMedCrossRef Devaney K, Snyder R, Norris HJ, Tavassoli FA. Proliferative and histologically malignant struma ovarii: a clinicopathologic study of 54 cases. Int J Gynecol Pathol 12(4):333–43, 1993.PubMedCrossRef
4.
5.
go back to reference Bolat F, Erkanli S, Kayaselcuk F, Aslan E, Tuncer I. Malignant struma ovarii: a case report. Pathol Res Pract 201(5):409–12, 2005.PubMedCrossRef Bolat F, Erkanli S, Kayaselcuk F, Aslan E, Tuncer I. Malignant struma ovarii: a case report. Pathol Res Pract 201(5):409–12, 2005.PubMedCrossRef
6.
go back to reference Makani S, Kim W, Gaba AR. Struma Ovarii with a focus of papillary thyroid cancer: a case report and review of the literature. Gynecol Oncol 94(3):835–9, 2004.PubMedCrossRef Makani S, Kim W, Gaba AR. Struma Ovarii with a focus of papillary thyroid cancer: a case report and review of the literature. Gynecol Oncol 94(3):835–9, 2004.PubMedCrossRef
7.
go back to reference Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Path 14(4):338–42, 2001.CrossRef Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Path 14(4):338–42, 2001.CrossRef
8.
go back to reference Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85(2):878–82, 2000.PubMedCrossRef Cheung CC, Ezzat S, Ramyar L, Freeman JL, Asa SL. Molecular basis of Hurthle cell papillary thyroid carcinoma. J Clin Endocrinol Metab 85(2):878–82, 2000.PubMedCrossRef
9.
go back to reference Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am J Surg Pathol 24(12):1622–6, 2000.PubMedCrossRef Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am J Surg Pathol 24(12):1622–6, 2000.PubMedCrossRef
10.
go back to reference Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28(10):1336–40, 2004.PubMedCrossRef Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, et al. Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28(10):1336–40, 2004.PubMedCrossRef
11.
go back to reference Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122(4):524–31, 2004.PubMedCrossRef Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol 122(4):524–31, 2004.PubMedCrossRef
12.
go back to reference Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch 445(2):183–8, 2004.PubMedCrossRef Volante M, Bozzalla-Cassione F, DePompa R, Saggiorato E, Bartolazzi A, Orlandi F, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch 445(2):183–8, 2004.PubMedCrossRef
13.
go back to reference Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6(4):292–306, 2006.PubMedCrossRef Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6(4):292–306, 2006.PubMedCrossRef
14.
go back to reference Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86(5):2187–90, 2001.PubMedCrossRef Cheung CC, Carydis B, Ezzat S, Bedard YC, Asa SL. Analysis of ret/PTC gene rearrangements refines the fine needle aspiration diagnosis of thyroid cancer. J Clin Endocrinol Metab 86(5):2187–90, 2001.PubMedCrossRef
15.
go back to reference Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio A, Fagin JA, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89(10):5175–80, 2004.PubMedCrossRef Salvatore G, Giannini R, Faviana P, Caleo A, Migliaccio A, Fagin JA, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 89(10):5175–80, 2004.PubMedCrossRef
16.
go back to reference Papotti M, Volante M, Giuliano A, Fassina A, Fusco A, Bussolati G, et al. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am J Surg Pathol 24(12):1615–21, 2000.PubMedCrossRef Papotti M, Volante M, Giuliano A, Fassina A, Fusco A, Bussolati G, et al. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am J Surg Pathol 24(12):1615–21, 2000.PubMedCrossRef
17.
go back to reference Schmidt JF, Heinrich M, Derr V, Corless CL, Fletcher JA, Nose V. BRAF, RAS, and RET mutations in malignant struma ovarii: a comparative study with benign struma ovarii. Mod Path 18(Suppl 1):945, 2005. Schmidt JF, Heinrich M, Derr V, Corless CL, Fletcher JA, Nose V. BRAF, RAS, and RET mutations in malignant struma ovarii: a comparative study with benign struma ovarii. Mod Path 18(Suppl 1):945, 2005.
18.
go back to reference Flavin R, Smyth P, Crotty P, Finn S, Cahill S, Denning K, et al. BRAF T1799A mutation occurring in a case of malignant struma ovarii. Int J Surg Pathol 15(2):116–20, 2007.PubMedCrossRef Flavin R, Smyth P, Crotty P, Finn S, Cahill S, Denning K, et al. BRAF T1799A mutation occurring in a case of malignant struma ovarii. Int J Surg Pathol 15(2):116–20, 2007.PubMedCrossRef
19.
go back to reference Elisei R, Romei C, Castagna MG, Lisi S, Vivaldi A, Faviana P, et al. RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration. Thyroid 15(12):1355–61, 2005.PubMedCrossRef Elisei R, Romei C, Castagna MG, Lisi S, Vivaldi A, Faviana P, et al. RET/PTC3 rearrangement and thyroid differentiation gene analysis in a struma ovarii fortuitously revealed by elevated serum thyroglobulin concentration. Thyroid 15(12):1355–61, 2005.PubMedCrossRef
20.
go back to reference LiVolsi VA. Surgical pathology of the thyroid. Philadelphia: Saunders, 1990. LiVolsi VA. Surgical pathology of the thyroid. Philadelphia: Saunders, 1990.
21.
go back to reference DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours. Lyons, France: IARC Press, 2004. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs. WHO classification of tumours. Lyons, France: IARC Press, 2004.
22.
go back to reference DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol 893:543–8, 2003.CrossRef DeSimone CP, Lele SM, Modesitt SC. Malignant struma ovarii: a case report and analysis of cases reported in the literature with focus on survival and I131 therapy. Gynecol Oncol 893:543–8, 2003.CrossRef
23.
go back to reference Rosenblum NG, LiVolsi VA, Edmonds PR, Mikuta JJ. Malignant struma ovarii. Gynecol Oncol 32(2):224–7, 1989.PubMedCrossRef Rosenblum NG, LiVolsi VA, Edmonds PR, Mikuta JJ. Malignant struma ovarii. Gynecol Oncol 32(2):224–7, 1989.PubMedCrossRef
Metadata
Title
Follicular Variant Papillary Thyroid Carcinoma Arising in Struma Ovarii
Authors
Odette Boutross-Tadross
Remaa Saleh
Sylvia L. Asa
Publication date
01-09-2007
Publisher
Humana Press Inc
Published in
Endocrine Pathology / Issue 3/2007
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-007-0022-8

Other articles of this Issue 3/2007

Endocrine Pathology 3/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.